Pompeo F, De Luca N, Marchegiano R, Gisonni P, Iovino G, D'Auria F, Del Mastro L, Simonelli P, Trimarco B
I Clinica Medica, Università degli Studi di Napoli Federico II.
Minerva Cardioangiol. 1994 Nov;42(11):511-5.
The carotid artery is one of the most important sites in the progression of atherosclerotic lesions. Atherosclerosis is known to be determined by a variety of factors, among which arterial hypertension is one of the most important. Blood pressure control by antihypertensive treatment is thus of great benefit in management of atherosclerosis, particularly in view of the direct action of some classes of antihypertensive agents on atheromatous lesions. Today, modern diagnostic technique allow a non-invasive examination of the artery wall (B-mode ultrasound and pulsed-Doppler), so that early detection of structural and functional alterations is possible. In order to evaluate the efficacy of the long term blood pressure reduction in the progression and/or in the regression of cardiovascular structural abnormalities, we studied intima-media thickness and arterial compliance during one-year antihypertensive treatment with a new calcium-antagonist, lacidipine, or a diuretic hydrochlorothiazide. In both groups we observed a comparable blood pressure reduction (lacidipine: from 166 +/- 5/100 +/- 1 to 142 +/- 4/88 +/- 2 mmHg; hydrochlorothiazide: from 154 +/- 5/102 +/- 2 to 140 +/- 4/88 +/- mmHg; both p < 0.01). On the contrary, only in patients treated with lacidipine did we obtain a significant improvement in carotid blood flow (383 +/- 16 vs 411 +/- 16 ml/min p <) and in arterial compliance (0.8 +/- 0.1 vs 1.2 +/- 0.2 cm/dyne p < 0.01). Indeed, we observed a different behaviour of the intima-media thickness in the two groups (lacidipine: 1.11 +/- 1.4 vs 1.13 +/- 1.5 mm n.s.; hydrochlorothiazide: 1.15 +/- 0.15 vs 1.21 +/- 0.17 mm p < 0.06). Our results demonstrate that an effective antihypertensive treatment with calcium antagonists may influence the progression of carotid vascular abnormalities.
颈动脉是动脉粥样硬化病变进展过程中最重要的部位之一。已知动脉粥样硬化由多种因素决定,其中动脉高血压是最重要的因素之一。因此,通过抗高血压治疗控制血压对动脉粥样硬化的管理非常有益,特别是考虑到某些类别的抗高血压药物对动脉粥样硬化病变的直接作用。如今,现代诊断技术允许对动脉壁进行无创检查(B型超声和脉冲多普勒),从而能够早期发现结构和功能改变。为了评估长期降低血压对心血管结构异常进展和/或消退的疗效,我们研究了使用新型钙拮抗剂拉西地平或利尿剂氢氯噻嗪进行一年抗高血压治疗期间的内膜中层厚度和动脉顺应性。在两组中,我们观察到血压有可比的降低(拉西地平:从166±5/100±1降至142±4/88±2 mmHg;氢氯噻嗪:从154±5/102±2降至140±4/88± mmHg;两者p<0.01)。相反,只有在用拉西地平治疗的患者中,我们才观察到颈动脉血流有显著改善(383±16对411±16 ml/min,p<)以及动脉顺应性有显著改善(0.8±0.1对1.2±0.2 cm/dyne,p<0.01)。事实上,我们观察到两组内膜中层厚度有不同表现(拉西地平:1.11±1.4对1.13±1.5 mm,无显著性差异;氢氯噻嗪:1.15±0.15对1.21±0.17 mm,p<0.06)。我们的结果表明,用钙拮抗剂进行有效的抗高血压治疗可能会影响颈动脉血管异常的进展。